Results 111 to 120 of about 45,532 (172)

Incidence and predictors of HBsAg loss following addition of pegylated interferon Alfa-2b in chronic hepatitis B patients suppressed by nucleos(t)ide analogues: a multicenter, prospective, cohort study. [PDF]

Virol J
Zhao J, Bian D, Xie D, Lv J, Lin L, Chen X, Zhang L, Feng B, Xu X, Lu F, Zheng S.   +10 more
europepmc   +1 more source

Refining surveillance of hepatocellular carcinoma in chronic hepatitis B through biomarker-based risk stratification. [PDF]

Hepatol Commun
Tseng TC, Huang SC, Kao JH.
europepmc   +1 more source

Combined HBsAg and anti-HBc testing is required to estimate hepatitis B virus seroprevalence in a low-endemic country: findings from a nationwide population-based serosurvey, Belgium, 2020. [PDF]

Euro Surveill
Furquim d'Almeida A, Ho E, Schüttler C, Beutels P, Hens N, Dudareva S, Van Damme P, Theeten H, Vanwolleghem T.   +8 more
europepmc   +1 more source

Interactions between hematological biomarkers of virus infection and immune cells in mediating distant metastasis in nasopharyngeal carcinoma: insights into prognosis and induction chemotherapy administration. [PDF]

Radiol Oncol
Li S, Chen B, Cao D, Luo C, Liang Z, Kou I, Ren G, Huang W, Ruan G, Liu L, Li H, Zhu S, Fei A.   +12 more
europepmc   +1 more source

Hepatitis B virus RNA and hepatitis B surface antigen kinetics predict treatment outcomes in children with chronic hepatitis B. [PDF]

Front Cell Infect Microbiol
Peng X, Chang Y, Wu J, Zhu J, Hu P, Ren H, Xu H, Zhao R, Qin T.   +8 more
europepmc   +1 more source

Add-on PD-1 inhibitor with Peg-IFNα therapy favors functional cure of chronic hepatitis B patients. [PDF]

J Transl Int Med
Li Y, Liu C, Yang L, He L, Li M, Gou G, Feng D, Zhang X, Wang F, Fu J, Dang S.   +10 more
europepmc   +1 more source

Trends in clinical intervention practice for preventing mother-to-child transmission of hepatitis B virus in Guangdong Province, 2021-2023. [PDF]

Hum Vaccin Immunother
Gao S, Xie T, Cai M, Su M, Zhao T, Zhang X, Zhang S, Wang M, Xu Q, Cheng Y, Cui F, Liu F.   +11 more
europepmc   +1 more source

Predicting loss of hepatitis B surface antigen and evaluating the durability of functional cure induced by pegylated interferon alpha: insights from a real-world study. [PDF]

PeerJ
Xu X, Huang JQ, Huang S.
europepmc   +1 more source

Combination therapy with tobevibart and elebsiran potently reduces hepatitis B virus surface antigen levels in preclinical <i>in vivo</i> models. [PDF]

Antimicrob Agents Chemother
Noack J, Anglero-Rodriguez Y, Gall J, Zhou J, LeBlanc S, Liebow A, Bakardjiev A, Hebner CM, Purcell LA, Jadhav V, Corti D, Lempp FA.   +11 more
europepmc   +1 more source

Towards HDV Elimination Through HBV Vaccination: Global Strategies, Challenges, and Policy Gaps. [PDF]

Vaccines (Basel)
Batbold E, Dashdorj N, Zoulim F, Bartosch B.   +3 more
europepmc   +1 more source